Group 1 - The European Society of Cardiology (ESC) annual meeting in Madrid showcased AstraZeneca's 32 groundbreaking studies in cardiovascular, renal, and metabolic diseases, highlighting the company's future plans in these areas [1] - Cardiovascular diseases (CVD) are a major global health burden, with rising incidence and mortality rates, prompting pharmaceutical companies to focus on innovative treatments [2][3] - AstraZeneca is addressing unmet patient needs in hypertension and chronic kidney disease through innovative drug development, particularly targeting aldosterone and exploring combination therapies [3][4] Group 2 - AstraZeneca's CVRM (Cardiovascular, Renal, and Metabolic) segment is a core growth engine, generating $6.512 billion in global revenue, accounting for 23% of the company's total performance [4] - The company aims to launch 20 breakthrough innovative drugs by 2030, targeting $80 billion in revenue, with CVRM playing a crucial role in this strategy [5] - AstraZeneca's global pipeline includes over 25 therapies across six core disease areas, with a focus on local innovation in China, enhancing treatment options for patients [6][7]